Abstract Number: 602 • 2015 ACR/ARHP Annual Meeting
Efficacy of Very Low Dose (100mg) Rituximab in Active Rheumatoid Arthritis Despite Combination DMARD-Single Center, Prospective, Observational Study
Background/Purpose: Rituximab is an anti-CD20 antibody that represents a therapeutic alternative for the patients with rheumatoid arthritis. It has been proven that rituximab at a…Abstract Number: 603 • 2015 ACR/ARHP Annual Meeting
Which Seronegative RA Patients Respond to Rituximab? – Preliminary Analysis of a Merged Clinical Trials Dataset
Background/Purpose: Seronegative RA patients have inferior clinical response to rituximab [1]. However, there is significant heterogeneity in this group of patients for baseline clinical features…Abstract Number: 751 • 2015 ACR/ARHP Annual Meeting
Rituximab Induced Serum Sickness: A Systematic Review
Background/Purpose: Rituximab (anti-CD20 monoclonal antibody) has been frequently used to treat various autoimmune diseases in which B-cells are participants, and for hematological malignancies in which…Abstract Number: 1040 • 2015 ACR/ARHP Annual Meeting
Factors Associated with Long Term Rituximab Use in Rheumatoid Arthritis – Results from the British Society of Rheumatology Biologics Register
Background/Purpose: Analysis of long term continuation of biologics in rheumatoid arthritis (RA) is considered a valid surrogate for treatment effectiveness and safety. Only a small…Abstract Number: 1569 • 2015 ACR/ARHP Annual Meeting
Rituximab Efficacy in the Treatment of Diffuse Interstitial Lung Disease Associated with Rheumatoid Arthritis
Background/Purpose: To investigate the efficacy and safety of rituximab (RTX) in the the management of progressive rheumatoid arthritis related interstitial lung disease (RA-ILD). Methods: An…Abstract Number: 2093 • 2014 ACR/ARHP Annual Meeting
Improvement of Rituximab Response Prediction in Rheumatoid Arthritis Via Correction for Prednisone-Related Suppression of Type I Interferon Response Gene Expression
Background/Purpose Elevated type I IFN response gene (IRG) expression has been described to be clinically relevant in predicting the non-response to rituximab in rheumatoid arthritis…Abstract Number: 1525 • 2014 ACR/ARHP Annual Meeting
Cumulative Clinical  Response in  Rheumatoid Arthritis Patients with  Rituximab Repeated Courses after Failure to Tumor Necrosis Factor Inhibitors in Routine Clinical Practice Â
Background/Purpose The concept of achieving tight control of rheumatoid arthritis (RA) and treating to target has been well established. It focuses on early diagnosis, aggressive…Abstract Number: 1539 • 2014 ACR/ARHP Annual Meeting
Relation Between Number of Previous Anti TNF Agents and Clinical Response in Rheumatoid Arthritis Patients Treated with Rituximab
Background/Purpose Debate is still ongoing regarding rituximab (RTX) as a first or second line biologic therapy. The objective of present study is to assess correlations between…Abstract Number: 1538 • 2014 ACR/ARHP Annual Meeting
Sustained Clinical Benefit with Multiple Courses of Rituximab in Second Line for All Rheumatoid Arthtritis Patients Irrespective to the Inhibitor of Tumour Necrosis Factor Previously Used
Background/Purpose: In the last decade, biologic therapy changed dramatically treatment options for rheumatoid arthritis (RA). However, a significant number of patients failed to maintain the…Abstract Number: 1508 • 2014 ACR/ARHP Annual Meeting
Impact of Anti-Drug Antibody on Efficacy and Safety over Week 24 in Both CT-P10 and Innovator Rituximab Treatment Groups
Background/Purpose CT-P10 is a biosimilar candidate for rituximab. Pharmacokinetic equivalence and similarity of clinical efficacy, safety and immunogenicity had been demonstrated between CT-P10 and Innovator…Abstract Number: 1502 • 2014 ACR/ARHP Annual Meeting
A Phase I Trial Comparing PF-05280586 (A Potential Biosimilar) and Rituximab in Subjects with Active Rheumatoid Arthritis
Background/Purpose: PF-05280586, a proposed biosimilar to rituximab, has the same primary amino acid sequence as rituximab with similar physicochemical and in vitro functional properties. This…Abstract Number: 1419 • 2014 ACR/ARHP Annual Meeting
Rituximab Use in Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease and Other Connective Tissue Disease-Associated Interstitial Lung Disease: A Single Center Experience
Background/Purpose: Small series have suggested that rituximab (RTX) may be effective as rescue-therapy for connective tissue disease-associated interstitial lung disease (CTD-ILD). We sought to describe…Abstract Number: 991 • 2014 ACR/ARHP Annual Meeting
The Alternative CD20 Transcript Variant Is Not a Factor for Resistance to Rituximab in Patients with Rheumatoid Arthritis
Background/Purpose: the identification of predictive factors for the response, or alternatively factors for resistance to biological agents is a relevant goal in the management of…Abstract Number: 844 • 2014 ACR/ARHP Annual Meeting
Frequency of Significant Infection in Patients with RA Following Initiation of Rituximab with up to 5 Years of Follow-up in a US Observational Study
Background/Purpose: Rituximab (RTX) is an approved treatment for rheumatoid arthritis (RA) in patients (pts) with an inadequate response to anti–TNF therapy (aTNF-IR). Long-term infection risk…Abstract Number: 2928 • 2014 ACR/ARHP Annual Meeting
Serum IL-33 Level Is Increased in Rheumatoid Arthritis and Predicts Response to Rituximab in Combination with High Serum IgG Level and Autoantibody Positivity: An Open-Label, Prospective, Multicentre Biological Trial
Background/Purpose . The recent discovered cytokine interleukin-33 (IL33) could be involved in B-cell activation as well as in RA pathophysiology. After a whole-blood transcriptomic analysis…